Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
1. A humanized monoclonal anti-Respiratory Syncytial Virus (RSV) antibody or antigen-binding fragment thereof, wherein the humanized monoclonal anti-RSV antibody or antigen binding fragment thereof comprises:
a variable heavy (VH) chain containing the complementary determining region 1 (CDR1) of SEQ ID NO:405 or SEQ ID NO:437, the complementary determining region 2 (CDR2) of SEQ ID NO:406, and the complementary determining region 3 (CDR3) of SEQ ID NO:407; and
a variable light (VL) chain containing the CDR1 of SEQ ID NO: 408, the CDR2 of SEQ ID NO: 409, and the CDR3 of SEQ ID NO:410.
2. The anti-RSV antibody or antigen-binding fragment of claim 1 , comprising:
a VH domain as set forth in amino acids 1-121 of SEQ ID NO:396; and
a VL domain as set forth in amino acids 1-110 of SEQ ID NO:395.
3. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment has an EC 50 of less than 2 nM for neutralization of RSV in an in vitro plaque reduction assay or an affinity of at least 10 8 M −1 for isolated RSV F protein or for RSV virus.
4. A multivalent humanized antibody, comprising:
a first antigen-binding portion comprising an antibody or antigen-binding fragment conjugated to a first multimerization domain, wherein said antibody or antigen-binding fragment comprises a variable heavy chain containing the CDR1 of SEQ ID NO:405 or SEQ ID NO:437, the CDR2 of SEQ ID NO:406, and the CDR3 of SEQ ID NO:407; and
a variable light chain containing the CDR1 of SEQ ID NO: 408, the CDR2 of SEQ ID NO: 409, and the CDR3 of SEQ ID NO:410; and
a second antigen-binding portion comprising an antigen-binding fragment of an antiviral antibody conjugated to a second multimerization domain, wherein:
the first multimerization domain and the second multimerization domain are complementary or the same, wherein the first antigen-binding portion and second antigen-binding portion form a multivalent antibody.
5. A pharmaceutical composition comprising:
a humanized monoclonal antibody of a non-human species or antigen-binding fragment thereof comprising a variable heavy chain containing the CDR1 of SEQ ID NO:405 or SEQ ID NO:437, the CDR2 of SEQ ID NO:406, and the CDR3 of SEQ ID NO:407; and
a variable light chain containing the CDR1 of SEQ ID NO: 408, the CDR2 of SEQ ID NO: 409, and the CDR3 of SEQ ID NO:410; and
a pharmaceutically acceptable carrier or excipient.
6. A method of treating or inhibiting one or more symptoms of a RSV infection, or for inhibiting a RSV infection in a subject, the method comprising:
administering to the subject an effective amount of the humanized monoclonal anti-RSV antibody or antigen-binding fragment of claim 1 so as to treat or inhibit one or more symptoms of a RSV infection, or for inhibiting a RSV infection.
7. A method of detecting RSV infection in a subject, the method comprising:
assaying the level of RSV antigen in a fluid, cell, or tissue sample from the subject utilizing the humanized monoclonal anti-RSV antibody or antigen-binding fragment of claim 1 ;
comparing the assayed level of RSV antigen with a control level wherein an increase in the assayed level of RSV antigen compared to the control level of the RSV antigen is indicative of an RSV infection.
8. An expression vector comprising:
a polynucleotide that encodes an antibody or antigen-binding fragment comprising:
a variable heavy chain containing the CDR1 of SEQ ID NO:405 or SEQ ID NO:437, the CDR2 of SEQ ID NO:406, and the CDR3 of SEQ ID NO:407; and
a variable light chain containing the CDR1 of SEQ ID NO: 408, the CDR2 of SEQ ID NO: 409, and the CDR3 of SEQ ID NO:410; and
regulatory nucleic acid molecules able to effect expression of the polynucleotide upon introduction of the expression vector into an appropriate host cell.
9. A conjugate comprising:
(a) an anti-Respiratory Syncytial Virus (RSV) antibody or antigen-binding fragment thereof that immunospecifically binds to a RSV fusion (F) protein, the anti-RSV antibody or antigen-binding fragment thereof comprising:
a variable heavy chain containing the CDR1 of SEQ ID NO:405 or SEQ ID NO:437, the CDR2 of SEQ ID NO:406, and the CDR3 of SEQ ID NO:407; and
a variable light chain containing the CDR1 of SEQ ID NO: 408, the CDR2 of SEQ ID NO: 409, and the CDR3 of SEQ ID NO:410; and
(b) a moiety conjugated to the anti-RSV antibody or antigen-binding fragment thereof, wherein the moiety is selected from the group consisting of a high molecular weight polyethylene glycol (PEG), a detectable moiety, and a therapeutic moiety.
10. The conjugate of claim 9 , wherein the moiety is PEG.
11. The conjugate of claim 9 , wherein the moiety is a detectable moiety comprising a label.
12. The conjugate of claim 9 , wherein the moiety is a therapeutic polypeptide.